COMP <GO>
SGP vs IRMD // EV/EBITDA & P/E VALUATION
SpyGlass Pharma Inc. (NASDAQ) VS. iRadimed Corporation (NASDAQ) • 15-METRIC TALLY: SGP 1
— IRMD 5
■ METRIC PARITY
LAST: $32.51 (-1.06%) • MKT CAP: $1.09B
valuation
—
LAST: $85.74 (+2.16%) • MKT CAP: $1.10B
valuation
31.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGP VS. IRMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SGP | IRMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 76.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 37.70% | -72.70 | IRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 31.9x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.08% | 1.57% | -4.65 | IRMD | /fcf-yield <GO> |
| Operating Margin | — | 31.20% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 26.80% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 14.40% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.37% | -1.37 | IRMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 8/9 | -6.00 | IRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.4 | 25.6 | +45.75 | SGP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 41.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.09B | $1.10B | -$9.0M | IRMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SGP REV | IRMD REV | SGP GROSS % | IRMD GROSS % | SGP FCF | IRMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $83.8M | — | 76.7% | -$33.5M | $17.2M |
| FY 2024 | $0 | $73.2M | — | 76.9% | -$24.0M | $17.6M |
| FY 2023 | — | $65.6M | — | — | — | $13.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGP // BETA —
IRMD // BETA —